Systemic Anaplastic Large Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Systemic Anaplastic Large Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma [Phase 3]
Soquelitinib is being studied in a Phase 3 trial versus standard of care for relapsed/refractory peripheral T-cell lymphomas, including PTCL…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma [Phase 4]
This is a Phase 4 trial of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma. The study is completed and…
-
CLINICAL_TRIALS trial_result · 2021-10-14Clinical Trial Update: A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer [Phase 1]
Phase 1 study of oral PF-02341066 (crizotinib) as a tyrosine kinase inhibitor targeting c-Met/HGF pathway in advanced cancers; study complet…
-
CLINICAL_TRIALS withdrawal · 2016-12-30Clinical Trial Update: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib [Phase 4]
A Phase 4 trial evaluating Crizotinib for systemic ALK-positive anaplastic large cell lymphoma has been withdrawn.
-
FDA approval · 2011-08-19FDA Approved: ADCETRIS — Original Application (SEAGEN INC.)
FDA approved ADCETRIS (brentuximab vedotin) in its original application for CD30-expressing classical Hodgkin lymphoma and systemic anaplast…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-08-19FDA Approved: ADCETRIS — Supplemental Application (SEAGEN INC.)
The FDA approved a supplemental application for ADCETRIS (brentuximab vedotin) submitted by Seagen Inc.
-
CLINICAL_TRIALS withdrawal · 2010-04-26Clinical Trial Update: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma [Phase 2]
This Phase 2 trial evaluating MDX-060 in relapsed or refractory anaplastic large cell lymphoma (systemic and primary cutaneous) has been wit…